semaglutide pediatric obesity trial
Semaglutide vs Tirzepatide Which Wins for Kids
In the June 2024 Novo Nordisk trial, semaglutide reduced obesity prevalence among children 6-12 by 15% after 52 weeks, making it the only GLP-1 currently approved for pediatric use, while tirzepatide remains off-label. Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult